By Business Wire, September 25, 2013, 08:00:00 AM EDT
RAMAT GAN, Israel--(BUSINESS WIRE)--
LabStyle Innovations Corp. (OTCQB:DRIO), developer of the Dario™
smartphone-based medical device and diabetes management system,
announces that Company management will participate in the Aegis Capital
2013 Healthcare Conference being held September 26-28, 2013 at The
Encore at Wynn Las Vegas.
Dr. Oren Fuerst, Executive Chairman and Erez Raphael, President and CEO,
will present a corporate overview on Friday, September 27 at 11:00 a.m.
Pacific time. The corporate presentation can be viewed at the Investors
section of the Company's website at www.mydario.com.
About LabStyle Innovations
LabStyle Innovations Corp. (OTCQB:DRIO) is developing and
commercializing a patent-pending technology that seeks to bring rapid
diagnostic capabilities to consumers in a distinctive and easy-to-use
way through the use of smartphones such as iPhones, Androids and other
mobile devices. LabStyle's initial product is Dario™, an integrated
medical device and software system addressing the market for diabetic
self monitoring of blood glucose (SMBG), a market which is estimated to
exceed $10 billion worldwide. Dario is a comprehensive, patent-pending
system that combines an all-in-one medical device consisting of an
integrated lancet (to obtain a blood sample), a device-specific
disposable test strip cartridge and a smartphone-driven glucose reader
adaptor, together with a smartphone app and cloud-based data services.
LabStyle is pursuing patent applications in multiple jurisdictions
covering the specific processes related to blood glucose level
measurement as well as more general methods of rapid tests of body
fluids using mobile devices and cloud-based services. For more
information, please visit www.mydario.com.
Cautionary Note Regarding Forward-Looking Statements
This news release, the investor presentation referred to herein, and the
statements of representatives and partners of LabStyle Innovations Corp.
(the Company) related thereto contains or may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Statements that are not statements of historical
fact may be deemed to be forward-looking statements. Without limiting
the generality of the foregoing, words such as "plan," "project,"
"potential," "seek," "may," "will," "expect," "believe," "anticipate,"
"intend," "could," "estimate" or "continue" are intended to identify
forward-looking statements. Readers are cautioned that certain important
factors may affect the Company's actual results and could cause such
results to differ materially from any forward-looking statements that
may be made in this news release. Factors that may affect the Company's
results include, but are not limited to, regulatory approvals, product
demand, market acceptance, impact of competitive products and prices,
product development, commercialization or technological difficulties,
the success or failure of negotiations and trade, legal, social and
economic risks, and the risks associated with the adequacy of existing
cash resources. Additional factors that could cause or contribute to
differences between the Company's actual results and forward-looking
statements include, but are not limited to, those risks discussed in the
Company's filings with the U.S. Securities and Exchange Commission.
Readers are cautioned that actual results may differ significantly from
those set forth in the forward-looking statements. The Company
undertakes no obligation to publicly update any forward-looking
statements, whether as a result of new information, future events or
otherwise, except as required by applicable law.
Source: LabStyle Innovations Corp.